Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
NQO1
REST API REST API
Homo sapiens
NQO1 is differentially expressed in 358 experiments: 150 organism parts: liver, trachea, ... (148 more);, 247 disease states: normal, colorectal adenocarcinoma, ... (245 more);, 126 cell types 534 cell lines 56 compound treatments and 79 other conditions.
Synonyms DTD, QR1, DIA4, DHQU, NMOR1
Orthologs nqo1 (Danio rerio)   Q3ZBH2_BOVIN (Bos taurus)   NQO1 (Gallus gallus)   Nqo1 (Mus musculus)   Nqo1 (Rattus norvegicus)   nqo1 (Xenopus laevis)   (Compare orthologs)
Gene Ontology Term cytosol, oxidoreductase activity, response to oxidative stress, protein binding, cytoplasm, response to toxin, nitric oxide biosynthetic process, coenzyme binding, negative regulation of catalytic activity, electron carrier activity, cytochrome-b5 reductase activity, NAD(P)H dehydrogenase (quinone) activity, xenobiotic metabolic process, synaptic transmission, cholinergic, positive regulation of neuron apoptosis, regulation of cellular amino acid metabolic process, cellular nitrogen compound metabolic process
InterPro Term Flavodoxin_fold, FMN_red
UniProt Accession B7ZAD1, B4DQP5, B4DLR8, P15559
Search EB-eye ENSG00000181019
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-6573, E-GEOD-3526, E-MTAB-62, E-TABM-125, ... (31 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, ... (48 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-20081, E-GEOD-19639, E-GEOD-3529, E-GEOD-5823
HL-60
3
E-GEOD-5258, E-MTAB-37, E-GEOD-24147
SW480
3
E-GEOD-18005, E-MEXP-1014, E-MTAB-37
A549
2
E-GEOD-3202, E-GEOD-6013
AGS
2
E-MTAB-37, E-GEOD-15460
BT20
2
E-MTAB-37, E-MTAB-62
528 more value(s).


Cell type

studied in E-GEOD-492, E-GEOD-20193, E-GEOD-3920, E-GEOD-20677, E-GEOD-2822, ... (52 experiments)

Factor Value U/D Experiments
monocyte
1
3
E-MEXP-2019, E-GEOD-11755, E-GEOD-995, E-GEOD-22373
CD8+ T cell
2
E-MTAB-25, E-AFMX-5
1
2
E-TABM-130, E-TABM-145
human foreskin fibroblast
2
E-GEOD-18265, E-GEOD-18147
human embryonic stem cell
1
2
E-GEOD-20033, E-GEOD-18265, E-GEOD-18147
endothelial cell
1
2
E-GEOD-19240, E-GEOD-96, E-GEOD-3920
120 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-MEXP-1121, E-TABM-15, ... (59 experiments)

Factor Value U/D Experiments
glioblastoma
4
E-GEOD-6014, E-MTAB-37, E-MTAB-62, E-GEOD-4412
lung adenocarcinoma
4
E-MTAB-37, E-MTAB-62, E-GEOD-2514, E-MEXP-231
colon carcinoma
3
E-MTAB-37, E-MTAB-62, E-MTAB-57
melanoma
3
E-MTAB-37, E-MTAB-62, E-GEOD-7307
lymphoma
2
E-MTAB-37, E-MTAB-62
AIDS-KS, HIV+, nodular (late) stage
1
2
E-MEXP-66, E-MTAB-62
241 more value(s).


Compound treatment

studied in E-GEOD-4668, E-GEOD-5741, E-TABM-782, E-GEOD-3720, E-GEOD-5824, ... (36 experiments)

Factor Value U/D Experiments
17beta-estradiol
4
2
E-GEOD-4668, E-GEOD-4006
cigarette smoke
2
E-TABM-127, E-MEXP-1512
lipopolysaccharide
2
E-MEXP-1958, E-GEOD-3720
PTTG
1
E-MEXP-2449
anti-CD3 antibody (clone:OKT3)
1
E-MEXP-1601
unknown
1
E-GEOD-7307
50 more value(s).


A rna yield

studied in E-TABM-325

Factor Value U/D Experiments
110.33
1
1
E-TABM-325
127.57
1
E-TABM-325


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37, E-GEOD-14359

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-GEOD-3320, E-MTAB-37, E-GEOD-5057, E-GEOD-994, ... (11 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-1614, E-GEOD-20033, E-MEXP-2359, E-GEOD-6236, E-GEOD-2666, ... (6 experiments)

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-3325, E-GEOD-22148, E-TABM-147, ... (7 experiments)

Environmental stress
studied in E-GEOD-1518, E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-MTAB-73, E-GEOD-7578, E-GEOD-17385, ... (9 experiments)

Genotype
studied in E-GEOD-2152, E-TABM-1029, E-GEOD-2466, E-GEOD-17476, E-GEOD-22593, ... (18 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-7011, E-MEXP-2657, E-GEOD-20540, E-TABM-440, E-GEOD-837, ... (17 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-20559, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-MEXP-2069, E-GEOD-1926, E-TABM-118, ... (37 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12254, E-GEOD-9723, E-MEXP-561, E-GEOD-6802, ... (6 experiments)

Injury
studied in E-GEOD-19743

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-7819, E-GEOD-21750, E-GEOD-1657

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, E-GEOD-19246, ... (7 experiments)

Qpcr egfr dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-10896, E-GEOD-17204

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-MEXP-548, E-GEOD-3697, ... (7 experiments)

Sample preparation
studied in E-GEOD-16728

sample status
studied in E-GEOD-30573

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

Stimulus or stress
studied in E-GEOD-7538

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-TABM-276, E-GEOD-2748

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-33562, E-GEOD-16837, E-MEXP-973, E-GEOD-21909, E-GEOD-19246, ... (10 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 99 146
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4271, E-GEOD-1561, E-GEOD-6532, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.48 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM